Castagna, Antonella

Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection

Segal-Maurer, S., DeJesus, E., Stellbrink, H.-J., Castagna, A., Richmond, G. J., Sinclair, G. I., Siripassorn, K., Ruane, P. J., Berhe, M., Wang, H., et al. (2022) · New England Journal of Medicine

HIV/AIDS drug development and treatmentHIV Research and Treatment

Cited by 331

Fast reshaping of intensive care unit facilities in a large metropolitan hospital in Milan, Italy: facing the COVID-19 pandemic emergency

Zangrillo, A., Beretta, L., Silvani, P., Colombo, S., Scandroglio, A. M., Dell’Acqua, A., Fominskiy, E., Landoni, G., Monti, G., Azzolini, M. L., et al. (2020) · Critical Care and Resuscitation

COVID-19 and healthcare impactsDisaster Response and Management

Cited by 221

Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection

Kozal, M., Aberg, J., Pialoux, G., Cahn, P., Thompson, M., Molina, J.-M., Grinsztejn, B., Diaz, R., Castagna, A., Kumar, P., et al. (2020) · New England Journal of Medicine

HIV/AIDS drug development and treatmentHIV Research and Treatment

Cited by 181

Residual clinical damage after COVID-19: a retrospective and prospective observational cohort study

De Lorenzo, R., Conte, C., Lanzani, C., Benedetti, F., Roveri, L., Mazza, M. G., Brioni, E., Giacalone, G., Canti, V., Sofia, V., et al. (2020) · PLoS ONE

Long-Term Effects of COVID-19COVID-19 Clinical Research Studies

Cited by 179

Candidemia in Coronavirus Disease 2019 (COVID-19) Patients: Incidence and Characteristics in a Prospective Cohort Compared With Historical Non–COVID-19 Controls

Mastrangelo, A., Germinario, B. N., Ferrante, M., Frangi, C., Li Voti, R., Muccini, C., Ripa, M., COVID-BioB Study Group, Canetti, D., Castiglioni, B., et al. (2021) · Clinical Infectious Diseases

Antifungal resistance and susceptibilityCOVID-19 Clinical Research Studies

Cited by 112

Bone mineral density and inflammatory and bone biomarkers after darunavir–ritonavir combined with either raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults with HIV-1: A substudy of the NEAT001/ANRS143 randomised trial

Bernardino, J. I., Mocroft, A., Mallon, P. W., Wallet, C., Gerstoft, J., Russell, C., Reiss, P., Katlama, C., De Wit, S., Richert, L., et al. (2015) · The Lancet HIV

HIV-related health complications and treatmentsHIV/AIDS drug development and treatment

Cited by 76

Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial

Moyle, G., Assoumou, L., de Castro, N., Post, F. A., Curran, A., Rusconi, S., De Wit, S., Stephan, C., Raffi, F., Johnson, M., et al. (2024) · The Lancet HIV

HIV/AIDS drug development and treatmentHIV/AIDS Research and Interventions

Cited by 6